scholarly article | Q13442814 |
P356 | DOI | 10.1016/J.IJPHARM.2016.10.052 |
P698 | PubMed publication ID | 27789367 |
P50 | author | Sanjay Garg | Q37831335 |
Xin-Fu Zhou | Q47432909 | ||
P2093 | author name string | Ankit Parikh | |
Chun Chuan Tan | |||
Krishna Kathawala | |||
P433 | issue | 1-2 | |
P407 | language of work or name | English | Q1860 |
P921 | main subject | edaravone | Q335099 |
bioavailability | Q461809 | ||
P304 | page(s) | 490-500 | |
P577 | publication date | 2016-10-24 | |
P1433 | published in | International Journal of Pharmaceutics | Q6051539 |
P1476 | title | Development of a novel oral delivery system of edaravone for enhancing bioavailability | |
P478 | volume | 515 |
Q30844551 | A staged screening of registered drugs highlights remyelinating drug candidates for clinical trials |
Q92134746 | Assessment of Fractional Factorial Design for the Selection and Screening of Appropriate Components of a Self-nanoemulsifying Drug Delivery System Formulation |
Q57181453 | Curcumin-loaded self-nanomicellizing solid dispersion system: part I: development, optimization, characterization, and oral bioavailability |
Q47700268 | How is edaravone effective against acute ischemic stroke and amyotrophic lateral sclerosis? |
Q38699643 | Lipid-based nanosystem of edaravone: development, optimization, characterization and in vitro/in vivo evaluation |
Q55686117 | Self-nanomicellizing solid dispersion of edaravone: part I – oral bioavailability improvement. |
Q60706687 | Self-nanomicellizing solid dispersion of edaravone: part II: in vivo assessment of efficacy against behavior deficits and safety in Alzheimer's disease model |
Q88437167 | Two Decades-Long Journey from Riluzole to Edaravone: Revisiting the Clinical Pharmacokinetics of the Only Two Amyotrophic Lateral Sclerosis Therapeutics |
Search more.